Drug application
IMIPENEM AND CILASTATIN (CILASTATIN SODIUM, IMIPENEM)
Drugs@FDA ANDA 090825 · HOSPIRA INC
Key facts
| Drug name | IMIPENEM AND CILASTATIN |
|---|---|
| Active ingredients | CILASTATIN SODIUM, IMIPENEM |
| Application type | ANDA |
| Application number | 090825 |
| Company | HOSPIRA INC |
| Dosage forms | POWDER, INTRAVENOUS |
| Strength | EQ 250MG BASE/VIAL;250MG/VIAL |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission status date | Nov 16, 2011 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
- Yes FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: